article
The promise of therapeutics from molecules within our body
In this article, senior leaders at SFA Therapeutics emphasise the importance of re-establishing homeostasis in drug development approaches.
List view / Grid view
Drug Development
article
Utilising engineered peptides for immunotherapy
In this Q&A, Dr DaeYong Lee discusses how a new method for building up natural immune response could lead to new immunotherapy drugs with safer toxicity profiles.
whitepaper
Beyond the lab: cell and gene therapy
Download this report now to access exclusive content on innovative cancer treatments, regenerative medicine, gene therapy, and expert insights from leading professionals in the field.
article
Women in Stem with Stefanie Flückiger-Mangual
Stefanie Flückiger-Mangual, Chief Executive Officer, is one of TOLREMO’s scientific founders and an expert in drug resistance in cancer therapy. She is a biomedical scientist and biochemist by training (University of Fribourg and ETH Zurich, Switzerland) and holds a PhD in Molecular and Translational Biomedicine from ETH Zurich. She led…
article
Machine learning’s growing importance in researching cells
As we move towards more generalised AI models, neural networks and natural language interfaces, we’re starting to see machine learning take the place of higher order reasoning and data analysis “sense making.” Traditional scientific inquiry has typically been about asking specific questions of a specific model system under specific conditions.…
news
New findings could influence asthma drug development
Researchers have revealed that genetically enhanced expression of GSDMB causes a disturbed interferon-response.
article
Unlocking the potential of antibody drug conjugates
Zymeworks’ Dr Paul Moore, Dr Raffaele Colombo and Dr Jamie Rich discuss how advancements in ADCs are redefining cancer treatment. They elucidate the innovative strategies that are being developed to improve drug stability and how personalised medicine approaches are optimising outcomes for individual cancer patients, offering new hope across several…
news
First animal model for Kaposi sarcoma developed
The mouse model provides a new understanding of the fundamental aspects of KSHV, which will enable drug and vaccine development.
article
Women in Stem with Laura Figulla
Dr Laura Figulla is the CEO of mbiomics. Laura co-founded mbiomics which is dedicated to unlocking the true value of the microbiome by developing next-generation live biotherapeutics (LBPs). Throughout her career, Laura has combined her entrepreneurial spirit with her diverse academic background in business, economics, and medicine to build companies that…
article
Overcoming the complexity of free energy perturbation calculations
In this article, Dr Robert Scoffin, Chairman and CEO at Cresset, explores FEP and its current challenges, and outlines how continuous advancements and strategic approaches are helping to drive the adoption of FEP methods in drug discovery.
article
Developing the next generation of antibody drug conjugates
In this Q&A, Léo Marx, Medicinal Chemistry Project Manager at Debiopharm, details how the therapeutic window of ADCs can be impacted, how we can overcome the challenges associated with achieving site-specific bioconjugation, and other essential considerations for optimising ADC performance.
article
Women in Stem with Lidia Pieri
Lidia Pieri earned a Master’s degree with honours in high energy physics at CERN, a PhD in theoretical astroparticle physics from Rome-3 (Italy) and an Executive MBA in Business Innovation with honours from the MIB school in Trieste. During the academic period she gained international exposure and recognition working as…
news
Drug-loaded 3D printed films could revolutionise liver cancer treatment
The new films killed over 80 percent of cancer cells, reduced recurrence rates and minimised undesirable chemotherapy side effects.
article
Pioneering the advancement of pre-targeted radioimmunotherapies
Although pre-targeting is still in its infancy, it has immense potential to increase state-of-the-art radioligand therapies. In this Q&A, PreTT reveals how their pre-targeted RLTs surpass traditional methods, transforming cancer treatment.
news
FOXO1 improves survival and function of CAR T cells
Evidence indicating that FOXO1 plays a unique role in promoting T cell longevity could result in more effective CAR T cell therapies.
